Lisi Zheng

State Key Laboratory Of Oncology In South China
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Author Correction: Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.

Author Correction: Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.

Journal: Nature cancer

Published: July 16, 2026

Correction: The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.

Correction: The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 27, 2026

SLC27A5 deficiency-induced reduction in long-chain fatty acid uptake is a pro-tumorigenic metabolic adaptation and confers sensitivity to glutaminase inhibition in hepatocellular carcinoma.

SLC27A5 deficiency-induced reduction in long-chain fatty acid uptake is a pro-tumorigenic metabolic adaptation and confers sensitivity to glutaminase inhibition in hepatocellular carcinoma.

Journal: Cancer letters

Published: March 31, 2026

ASB7 is a negative regulator of H3K9me3 homeostasis.

ASB7 is a negative regulator of H3K9me3 homeostasis.

Journal: Science (New York, N.Y.)

Published: May 29, 2025

The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.

The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 14, 2024

Targeting RBM39 suppresses tumor growth and sensitizes osteosarcoma cells to cisplatin.

Targeting RBM39 suppresses tumor growth and sensitizes osteosarcoma cells to cisplatin.

Journal: Oncogene

Published: May 16, 2024

Targeting the KAT8/YEATS4 Axis Represses Tumor Growth and Increases Cisplatin Sensitivity in Bladder Cancer.

Targeting the KAT8/YEATS4 Axis Represses Tumor Growth and Increases Cisplatin Sensitivity in Bladder Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: December 23, 2023

Augmenting L3MBTL2-induced condensates suppresses tumor growth in osteosarcoma.

Augmenting L3MBTL2-induced condensates suppresses tumor growth in osteosarcoma.

Journal: Science advances

Published: November 22, 2023

NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer.

NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer.

Journal: Cell reports

Published: October 05, 2022

Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.

Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.

Journal: Nature cancer

Published: April 26, 2022

Knockdown of ZBTB11 impedes R-loop elimination and increases the sensitivity to cisplatin by inhibiting DDX1 transcription in bladder cancer.

Knockdown of ZBTB11 impedes R-loop elimination and increases the sensitivity to cisplatin by inhibiting DDX1 transcription in bladder cancer.

Journal: Cell proliferation

Published: March 09, 2022

CREB1 contributes colorectal cancer cell plasticity by regulating lncRNA CCAT1 and NF-κB pathways.

CREB1 contributes colorectal cancer cell plasticity by regulating lncRNA CCAT1 and NF-κB pathways.

Journal: Science China. Life sciences

Published: February 21, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026